Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F R Robertson

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancerW Jonat, T Bachelot, T Ruhstaller, et al.
Breast Cancer Research and Treatment|June 27, 2003
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapyI Vergote, J F R Robertson, U Kleeberg, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2010
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal womenK L Cheung, A Agrawal, E Folkerd, et al.
Endocrine-Related Cancer|August 23, 2005
Overview of tyrosine kinase inhibitors in clinical breast cancerA Agrawal, E Gutteridge, J M W Gee, et al.
Breast (Edinburgh, Scotland)|October 20, 2009
Neoadjuvant endocrine treatment in primary breast cancer - review of literatureJ Mathew, K S Asgeirsson, L R Jackson, et al.
Journal of Public Health (Oxford, England)|May 10, 2017
Factors influencing the decision to attend screening for cancer in the UK: a meta-ethnography of qualitative researchB Young, L Bedford, D Kendrick, et al.
Critical Reviews in Oncology/Hematology|September 25, 2002
HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatmentR S Rampaul, S E Pinder, W J Gullick, et al.
The Journal of Peptide Research : Official Journal of the American Peptide Society|December 1, 2005
Malignancy-induced autoimmunity to MUC1: initial antibody characterizationC R L Graves, J F R Robertson, A Murray, et al.
Breast Cancer Research and Treatment|June 30, 2005
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrantJ F R Robertson, A Howell, V A Gorbunova, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 27, 2008
Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directionsJ Mathew, K S Asgeirsson, K L Cheung, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancerW Jonat, T Bachelot, T Ruhstaller, et al.
Breast Cancer Research and Treatment|June 27, 2003
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapyI Vergote, J F R Robertson, U Kleeberg, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2010
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal womenK L Cheung, A Agrawal, E Folkerd, et al.
Endocrine-Related Cancer|August 23, 2005
Overview of tyrosine kinase inhibitors in clinical breast cancerA Agrawal, E Gutteridge, J M W Gee, et al.
Breast (Edinburgh, Scotland)|October 20, 2009
Neoadjuvant endocrine treatment in primary breast cancer - review of literatureJ Mathew, K S Asgeirsson, L R Jackson, et al.
Journal of Public Health (Oxford, England)|May 10, 2017
Factors influencing the decision to attend screening for cancer in the UK: a meta-ethnography of qualitative researchB Young, L Bedford, D Kendrick, et al.
Critical Reviews in Oncology/Hematology|September 25, 2002
HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatmentR S Rampaul, S E Pinder, W J Gullick, et al.
The Journal of Peptide Research : Official Journal of the American Peptide Society|December 1, 2005
Malignancy-induced autoimmunity to MUC1: initial antibody characterizationC R L Graves, J F R Robertson, A Murray, et al.
Breast Cancer Research and Treatment|June 30, 2005
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrantJ F R Robertson, A Howell, V A Gorbunova, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 27, 2008
Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directionsJ Mathew, K S Asgeirsson, K L Cheung, et al.
Pageof 5